Belotecan

Summary

Belotecan (CHEMBL2111084) is a phase-3 clinical-stage small molecule (ATC L01CE04); indicated across 5 conditions including small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01CE04
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 433.5 Da · C25H27N3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111084
Name	Belotecan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6456014
ATC	L01CE04
Molecular formula	C25H27N3O4
Molecular weight	433.5
InChIKey	LNHWXBUNXOXMRL-VWLOTQADSA-N

SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CCNC(C)C)O

IUPAC name: (19S)-19-ethyl-19-hydroxy-10-[2-(propan-2-ylamino)ethyl]-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione

Also known as: Belotecan, BELOTECAN, belotecan

Parent form; salt/anhydrous children: CHEMBL2107315

Patent coverage: 2,057 distinct patent families (5,824 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,594 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
neoplasm	3	MONDO:0005070	EFO:0000616
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
ovarian cancer	2	MONDO:0008170	MONDO:0008170

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00826644	PHASE3	COMPLETED	Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
NCT01022671	PHASE2	COMPLETED	Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy
NCT01497873	PHASE2	COMPLETED	A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
NCT01630018	PHASE2	COMPLETED	Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
NCT01784107	PHASE1/PHASE2	UNKNOWN	A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).